Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21944901 | 0.82 | IDO1 (0.56) | IDO1MRGPRX4PTGDR2SLC6A4GPR84 | |
| SCHEMBL18002421 | 0.82 | IDO1 (0.50) | IDO1MRGPRX4PTGDR2SLC6A4MAOB | |
| SCHEMBL21944990 | 0.79 | MAOB (0.49) | MRGPRX4MAOB | |
| SCHEMBL5505912 | 0.77 | IDO1 (0.60) | IDO1MRGPRX4PTGDR2SLC6A4GPR84 | |
| SCHEMBL21945013 | 0.77 | MAOB (0.62) | IDO1MRGPRX4MAOB | |
| SCHEMBL21944797 | 0.76 | SMN1; SMN2 (0.46) | MRGPRX4 | |
| SCHEMBL21944575 | 0.76 | SRD5A2 (0.45) | MRGPRX4SLC6A4MAOB | |
| SCHEMBL21944816 | 0.75 | NR4A2 (0.47) | MAOB | |
| SCHEMBL25140232 | 0.75 | MAPT (0.42) | MRGPRX4MAOB | |
| SCHEMBL6239485 | 0.75 | PTGDR2 (0.66) | IDO1MRGPRX4PTGDR2S1PR1KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | IDO1 2430/4885MRGPRX4 4062/4885PTGDR2 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.